Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Li, Maolan ^a   Shen, Jun ^a   Wu, Xiangsong ^a   Zhang, Bingtai ^b   Zhang, Rui ^c   Weng, Hao ^a   Ding, Qian ^a   Tan, Zhujun ^a   Gao, Guofeng ^b   Mu, Jiasheng ^a   Yang, Jiahua ^a   Shu, Yijun ^a   Bao, Runfa ^a   Ding, Qichen ^a   Wu, Wenguang ^a   Cao, Yang ^a   Liu, Yingbin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c The Affiliated Hospital of Inner Mongolia Medical University   (China)

Author keywords

Cell proliferation; Gallbladder cancer; Hepatoma derived growth factor; RNA interference

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER CELL CULTURE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SURVIVAL TIME; BIOSYNTHESIS; CELL GROWTH; CELL NUCLEUS; CHEMISTRY; CHI SQUARE DISTRIBUTION; DOWN REGULATION; GALLBLADDER TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84876295199     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0587-7     Document Type: Article

References (20)

1. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695-706.
2. Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: past, present and an uncertain future. Surg Oncol. 2012;21(4):e183-91.
3. Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009;281(1):71-81.
4. Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315(4):950-8.
5. Bremer S, Klein K, Sedlmaier A, Abouzied M, Gieselmann V, Franken S. Hepatoma- derived growth factor and nucleolin exist in the same ribonucleoprotein complex. BMC Biochem. 2013;14:2. doi: 10.1186/1471-2091-14-2.
6. Lin YW, Li CF, Chen HY, Yen CY, Lin LC, Huang CC, et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012;48(7):629-35.
7. Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008;99(11):2120-7.
8. Liao F, Dong W, Fan L. Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med Oncol. 2010;27(4):1219-26.
9. Meng J, Xie W, Cao L, Hu C, Zhe Z. shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin. 2010;42(1):52-7.
10. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol. 2007;14(7):2141-9.
11. Chen X, Yun J, Fei F, Yi J, Tian R, Li S, et al. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract. 2012;208(8):437-43.
12. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006;12(20 Pt 1):6043-8.
13. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008;452(2):139-46.
14. Li ML, Wang XF, Tan ZJ, Dong P, Gu J, Lu JH, et al. Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-rage axis. Int J Immunopathol Pharmacol. 2012;25(4):955-65.
15. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009;8(5):1106-12.
16. Kung ML, Tsai HE, Hu TH, Kuo HM, Liu LF, Chen SC, et al. Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2012;425(2):169-76.
17. Hsu SS, Chen CH, Liu GS, Tai MH, Wang JS, Wu JC, et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol. 2012;107(1):101-9.
18. Sasaki Y, Negishi H, Idogawa M, Yokota I, Koyama R, Kusano M, et al. p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res. 2011;71(22):7038-47.
19. Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial - mesenchymaltransition. J Pathol. 2012;228(2):158-69.
20. Zhou Y, Zhou N, Fang W, Huo J. Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol. 2010;5:58. doi: 10.1186/1746-1596-5-58.